atai Life Sciences

Contributing Author

Recent Articles by atai Life Sciences

Oct-20	atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares ATAI GlobeNewswire
Oct-16	atai Life Sciences Announces Pricing of Public Offering of Common Shares ATAI GlobeNewswire
Oct-16	atai Life Sciences Announces Proposed Public Offering of Common Shares ATAI GlobeNewswire
Oct-16	atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression ATAI GlobeNewswire
Sep-23	atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression ATAI GlobeNewswire
Sep-18	atai Life Sciences Awarded Grant from the National Institutes of Health ATAI GlobeNewswire
Aug-28	atai Life Sciences to Participate in September Investor Conferences ATAI GlobeNewswire
Aug-14	atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates ATAI GlobeNewswire
Jul-25	Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia ATAI GlobeNewswire
Jul-01	atai Life Sciences Announces $50 Million Private Placement Financing ATAI GlobeNewswire
Jul-01	atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression ATAI GlobeNewswire
Jun-02	atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies ATAI GlobeNewswire
May-29	atai Life Sciences to Participate in Upcoming Investor Conferences ATAI GlobeNewswire
May-20	atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression ATAI GlobeNewswire
May-14	atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates ATAI GlobeNewswire
May-13	atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder ATAI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.